Publication:
Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process

dc.creatorChen, Chin‑Fu;Lu, Chi‑Cheng;Chiang, Jo‑Hua;Chiu, Hong‑Yi;Yang, Jai‑Sing;Lee, Chao‑Ying;Way, Tzong‑Der;Huang, Hao‑Jen
dc.date2018-11
dc.date.accessioned2020-01-07T02:28:08Z
dc.date.accessioned2025-07-27T15:02:13Z
dc.date.available2020-01-07T02:28:08Z
dc.date.issued2020-01-07T02:28:08Z
dc.description.abstractCetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody (mAb), is a novel targeted therapy for the treatment of patients with oral cancer. Cetuximab can be used in combination with chemotherapeutic agents to prolong the overall survival rates of patients with oral cancer. Curcumin is a traditional Chinese medicine, and it has been demonstrated to have growth‑inhibiting effects on oral cancer cells. However, information regarding the combination of cetuximab and curcumin in drug‑resistant oral cancer cells is lacking, and its underlying mechanism remains unclear. The purpose of the present study was to explore the oral anticancer effects of cetuximab combined with curcumin on cisplatin‑resistant oral cancer CAR cell apoptosis in vitro. The results demonstrated that combination treatment synergistically potentiated the effect of cetuximab and curcumin on the suppression of cell viability and induction of apoptosis in CAR cells. Cetuximab and curcumin combination induced apoptosis and dramatically increased caspase‑3 and caspase‑9 activities compared with singular treatment. Combination treatment also markedly suppressed the protein expression levels of EGFR and mitogen‑activated protein kinases (MAPKs) signaling (phosphorylation of ERK, JNK and p38). The results demonstrated that co‑treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway.
dc.format.extent137 bytes
dc.format.mimetypetext/html
dc.identifier.urihttps://ir.ntus.edu.tw/handle/987654321/64184
dc.languagezh_TW
dc.publisherSpandidos Publications
dc.relationOncology Letters, Vol.16, No.5, pp.6323-6330
dc.subjectCetuximab; Curcumin; Epidermal Growth Factor Receptor; MAPK Signaling; Cisplatin-resistant Oral Cancer CAR cells
dc.titleSynergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process
dc.typearticle
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
index.html
Size:
137 B
Format:
Hypertext Markup Language
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
703 B
Format:
Plain Text
Description:

Collections